Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Akston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countries17-03-2022
17-03-2022
Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding request received for loss of share certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 R. Hariharan16-03-2022
Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 16, 2022 for Pronomz Ventures LLP and Arun Kumar Pillai16-03-2022
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of Newspaper Advertisement w.r.t. Extraordinary General Meeting on April 7, 2022 in compliance with Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201515-03-2022
Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for SBI Funds Management Ltd14-03-2022
Strides Pharma Science Ltd - 532531 - Notice Of Extraordinary General Meeting
Notice of Extraordinary General Meeting14-03-2022
Strides Pharma Science Ltd - 532531 - Update On Proposed Preferential Issue
Update on Proposed Preferential Issue14-03-2022
Strides Pharma unit gets USFDA for generic product
Singapore-based Strides Pharma Global Pte, a step down wholly-owned subsidiary of the company, has received approval from the United States Food Drug Administration (USFDA) to market the product, Strides Pharma Science said in a statement.11-03-2022
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides receives USFDA approval for Colchicine Tablets11-03-2022
Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd05-03-2022